Related Experiment Videos
[Adverse reactions to antitubercular treatment with rifampin (Considerations on 14 cases]
Abstract:
An analysis of a group of 120 patients with pulmonary tuberculosis undergoing rifampicin treatment attempted to perform a study of adverse reactions induced by this drug used in modern therapeutic regimens of short duration (6 to 9 months). This was prompted by the increasing number of papers in the specialized literature concerned with such adverse reactions that occur in 10--50 percent of all cases treated with rifampicin. Adverse reactions to rifampicin (influenza-like syndrome, digestive syndrome, hepatic syndrome) were relatively rare in the group presented here (11,8 percent), when compared with the data in the literature. Although no severe adverse reactions occured, suppression of rifampicin therapy was necessary in most of the cases, and this modified the efficiency of the treatment. This low incidence has however a statistical significance indicating that larger groups should be investigated.
Insights
Adverse reactions to rifampicin in pulmonary tuberculosis patients were rare (11.8%) in this study. However, these reactions often necessitated treatment modification, impacting therapeutic efficacy.
Area of Science:
- Medicine
- Pharmacology
- Infectious Diseases
Background:
- Rifampicin is a key drug in short-course tuberculosis treatment regimens.
- Published literature reports significant adverse reactions to rifampicin (10-50% of cases).
- Understanding rifampicin's adverse effects is crucial for optimizing tuberculosis therapy.
Purpose of the Study:
- To analyze the incidence and nature of adverse reactions to rifampicin in pulmonary tuberculosis patients.
- To compare observed adverse reaction rates with existing literature data.
- To assess the impact of adverse reactions on treatment outcomes.
Main Methods:
- A cohort of 120 pulmonary tuberculosis patients receiving rifampicin treatment was analyzed.
- Adverse reactions, including influenza-like, digestive, and hepatic syndromes, were documented.
- Treatment modifications due to adverse events were recorded.
Main Results:
- Adverse reactions to rifampicin occurred in 11.8% of the studied patient group.
- Observed incidence was lower than reported in previous literature.
- No severe adverse reactions were noted, but treatment was often suppressed or modified.
Conclusions:
- Rifampicin adverse reactions may be less common than previously suggested, warranting further investigation in larger cohorts.
- Even non-severe adverse reactions can necessitate treatment adjustments, potentially affecting tuberculosis treatment efficacy.
- Further research with larger patient groups is recommended to confirm these findings.